Article
A significant proportion of patients with rheumatologic disease are of reproductive age, therefore, navigating reproductive health is now widely recognized as a fundamental component of modern rheumatology care.
All News
Article
Sun Pharmaceuticals announced Friday that the FDA has approved its IL-23 inhibitor, tildrakizumab (Ilumya) for use in patients with active psoriatic arthritis.
Dr. John Cush
Tweet
Spanish Nationwide registry study of 5120 hospitalised #GCA pts (2016-2024) found that 54 (1.1%) Dx / aortic aneurysm (AA) & 41 (0.8%) developed AA on F/U (AAf group). Median time to AA Dx 2.7 yrs. AA Risk was higher in males (RRR 2.42) & smoking w/ GCA (RRR 3.23) https://t.co/eZVGKbOfQt
Dr. John Cush
Tweet
THe the International Federation of Psoriasis Associations has announced that the 8th World Psoriasis & Psoriatic Arthritis Conference will be taking place in Stockholm on 20–22 May 2027. Registration is open. https://t.co/lq5XdcZlki https://t.co/AYGCnwzeue https://t.co/fy6UUCbcxf
Peter Nash
Tweet
AxSpA SIG Baraliakos - CD74 abs in SpA - what other abs need exploration?
@RheumNow #APLAR2026 https://t.co/rftgYQH4mX
sheila
Tweet
Key messages from Dr. Vaidya’s talk:
- Assocn’s of hyperuricemia or gout with MetS shows a bidirectional trend
- Causality: MetS as an upstream driver for gout devt
Going beyond jt dse & ULT. What addt’l assessments do you do for your gout pts?
@RheumNow #APLAR2026 https://t.co/M6XVoRQ5rz
Jiha Lee
Tweet
Perspective from dentists on SjD dry mouth: muscarinic agonists (pilocarpine, cevimeline) help, but side effects limit use. Two ways to improve it: split pilocarpine dosing (2.5 mg four times daily) and a cevimeline mouth rinse in 6 or more divided doses. #APLAR26 @RheumNow https://t.co/phiLD0qaoR
Jiha Lee
Tweet
@RheumNow Do the two fixes work? Split pilocarpine (n=20 SjD, 4 weeks): sweating severity 3.7 to 1.7 (p<0.001), oral dryness VAS 61.0 to 43.6 (p=0.011). Cevimeline rinse (n=12 SjD): unstimulated salivary flow higher than juice control at 1 and 2 h. Small studies. #APLAR26 @RheumNow https://t.co/LEDHFGwh8Q
sheila
Tweet
Lupus/LN should not be a sole indication for a C-section
C-section should be reserved for obstetric indications.
Adapt a multidisciplinary approach.
@RheumNow #APLAR2026 https://t.co/vrXeNP9xLI
sheila
Tweet
There is physiologic proteinuria in pregnancy so be careful before attributing a rise of levels to active LN
LN flare vs. pre-eclampsia: both can present w/ HTN, edema, low plts and inc crea.
> monitor C3 changes during each trimester of pregnancy
@RheumNow #APLAR2026 https://t.co/Pp6GGeLPC6
Jiha Lee
Tweet
Monitoring ILD in SjD: reassess risk at every visit. High risk with disease duration under 1 year: PFTs every 3-6 months, HRCT at 1 year. Lung biopsy has no role in diagnosis, except for atypical HRCT features or to exclude malignancy. #APLAR26 @RheumNow https://t.co/tFPNi0S8y8
sheila
Tweet
The growing unmet needs of repro health in the @APLAR_org region lead to dev’t of new consensus statements
Provides a practical guide for rheums focusing on key areas like preconception, meds safety in pregnancy & men w/AIRDs planning to become fathers etc
@RheumNow #APLAR2026 https://t.co/xCKmpcD4ma
Jiha Lee
Tweet
Same molecule, different route, different persistence: golimumab IV persisted 4.44 yrs vs 2.07 for SC in biologic-naive RA (n=9,464, Korean claims). Is it the route, or differenntial out of pocket cost, or supervised dosing and better adherence? P#240 #APLAR26 @RheumNow
Jiha Lee
Tweet
Older adults with RA on JAKi: filgotinib may carry a lower zoster risk than others. Is it JAK1 selectivity? UPA (available in the US) is also selective. Dose, zoster vaccination status and a mixed comparator group may matter. Day 3 Abst Session 7 #APLAR26 @RheumNow https://t.co/5ri4shAHnV
sheila
Tweet
This interesting study by @doktora_ging et al describes the notable differences in skin lesions bet Filipino vs caucasian.
Fil skin: darker lesions, marked contrast bet hypo/hyperpigmentation, more gray & black psor plaques
Practical & informative.
@RheumNow #APLAR2026 https://t.co/A1dyFRNkwV
sheila
Tweet
Guidelines similar for GC use in pregnancy.
For @APLAR_org , non-fluorinated gcs are recommended and much lower doses of prednisone <5mg/day as the target with IV MP preferred for severe disease.
Universal recos to monitor BP, glucose and steroid-related SEs
@RheumNow #APLAR https://t.co/FrQEsbLbOk
Dr. John Cush
Tweet
Does IVIG have a Role in Scleroderma?
A recent systemic review and meta-analysis by Jozelio Freire de Carvalho and colleagues analyzed the available literature on this therapy. This study, published in Frontiers in Immunology in October 2026, evaluated the available evidence https://t.co/a8J2UT2I7Y
Dr. John Cush
Tweet
Beyond Chondrocalcinosis - What’s New in CPPD Disease
An overview of calcium pyrophosphate deposition (CPPD) disease by Sara Tedeschi presents our evolving understanding of CPPD with advances affecting nomenclature, classification, imaging, genetics, long-term outcomes and https://t.co/HmDgB9nNbm
Dr. John Cush
Tweet
Tocilizumab is effective in glucocorticoid-resistant adult-onset Still’s dz. 40 AOSD pts rx w/ TCZ (4-8 mg/kg q4wks). @12 mos clin remission 55%, 6 mos CID 62%, signif drops in CRP, ESR, ferritin & daily pred decr 91% (50 to 4.4 mg; p<0.001). TCZ retention 65%; MAS 7.5% & https://t.co/jtAxrz6ETd
Dr. John Cush
Tweet
Long term F/U of 80 systemic sclerosis pts Rx w/ autologous HSCT. W/ Med. 9.2 yrs F/U progression-free survival = 81%, 72% @5 yrs, & 60% @10 yrs. 18 pts died; death due to HSCT in 6%, SSc progression in 11%, CA in 2 (3%), serious infx 2 (3%), 34 (43%) maintained remission without https://t.co/l6RUf2Zqyw
